DOCSLIB.ORG

United States Patent (19) 11) Patent Number: 5,620,964 Roth Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11) Patent Number: 5,620,964 Roth Et Al USOO5620964A United States Patent (19) 11) Patent Number: 5,620,964 Roth et al. 45) Date of Patent: Apr. 15, 1997 54) COMPOSITIONS FORTREATING AND Podolsky, J. of Biological Chemistry vol. 260, No. 14, pp. NHBITING GASTRIC AND DUODENAL 8262-82.71. ULCERS Evans, et al., Infection and Immunity(1988) 56: 2896–2906. Evans, et al., Infection and Immunity(1989) 57:2272-2278. 75 Inventors: Stephen Roth, Gladwyne; Edward J. Lingwood, et al., The Lancet(1989) 2:238-241. McGuire, Furlong, both of Pa.; Dennis H. Langer, Princeton, N.J. (List continued on next page.) 73) Assignee: Neose Technologies, Inc., Horsham, Pa. Primary Examiner-John W. Rollins Assistant Examiner-Francisco C. Prats (21) Appl. No.: 461,000 (57) ABSTRACT (22 Filed: Jun. 5, 1995 A composition for treating and/or inhibiting gastric and duodenal ulcers, comprising an oligosaccharide selected Related U.S. Application Data from the group consisting of Formula I 63 Continuation of Ser. No. 104.483, Jul. 28, 1993, abandoned, OHO-W" O-W which is a continuation-in-part of Ser. No. 922,519, Jul. 31, 1992, abandoned. O H. O (51) Int. Cl. .................................... A61K 3/715 W-O O O-Y; 52 U.S. Cl. ................................ 514/53; 514/42, 514/54; OH X 514/58; 514/61; 514/925; 514/926; 514/927 O -W" Formula II 58) Field of Search .................................. 514/42, 53, 58, H - O O-W 514/61, 925,926,927, 54 O O 56) References Cited W-O O O-Y OH HO X U.S. PATENT DOCUMENTS or a mixture thereof; wherein: 4,935,406 6/1990 Colmena et al. ......................... 514/54 4,938,967 7/1990 Newton et al. .. ... 424/458 X is independently OH or NHAc; 5,318,780 6/1994 Wiegas et al. ........................... 424/427 Y is independently H, or an amino acid or a peptide of OTHER PUBLICATIONS 2-100, preferably 2-20, amino acids; and Boren et al., Science, vol. 262, 1892-1895 17 Dec. 1993. W, W, and W" are each independently H or Evans et al., Journal of Bacteriology, Feb. 1993, pp. 674-683, vol. 15, No. 3. HO Saitoh et al., Federation of European Biochemical Societies, May 1991, vol. 282, No. 2 385-387. O CO2Z; Lingwood, et al., Infection and Immunity, Jul. 1993, pp. HO 2 2474-2478, vol. 61, No. 6. Fauchere, et al., Microbial Pathogenesis 1990:9: 427-439. Lingwood, et al., Infection and Immunity, Jun. 1992, pp. where Z is independently H or a pharmaceutically 2470-2474, vol. 60, No. 6. acceptable cation, and Robinson, et al., J. Med. Microbiol., vol. 33 (1990). P is independently H or 277-284, 1990 The Pathological Society of Great Britain and Ireland. HO Figueroa, et al., Journal of Infection (1992) 24,263-267. HO Talley, et al., Journal of the National Cancer Institute (1991) AcNH O COZ 83, 1734-1739. HO Wotherspoon, et al., The Lancet, vol. 342, Sep. 4, 1993, pp. 575-577. OH Russell, et al., The Lancet, vol. 342, Sep. 4, 1993, pp. 571-574. where Z is defined as above; National Institutes of Health, Concensus Development Con wherein at least one of W, W" or W" is an O-N- ference Statement, Helicobacter pylori in Peptic Ulcer Dis acetylneuraminic acid moiety, and ease, Feb. 7–9, 1994, 19 pages. wherein W" and W" are not simultaneously o-N-acetyl Falk, et al., Proc. Natl. Acad. Sci, USA, vol. 90 pp. neuraminic acid moiety 2035-2039, Mar. 1993. with the proviso that the compound of Formula II is not Huang, et al., Journal of General Microbiology (1992), 138, NAN o(2-3)Gal B1-4 Glu or NAN O(2-6)Gal 1503-153. 31-4 Glu; and a kit for detecting the presence of Koybayashi et al., Infection and Immunity, Oct. 1993, pp. Helicobacter pylori comprising at least one com 4058-4063. vol. 61, No. 10. pound of the Formula I or II, are described. Clyde, et al., Infection and Immunity, Oct. 1993, pp. 4058-4063, vol. 61, No. 10. 19 Claims, No Drawings 5,620,964 Page 2 OTHER PUBLICATIONS Mizuochi et al., J. Biological Chemistry, 255(8):3526–3531, (1980). Tzouvelekis, et al., Infection and Immunity(1991) 59.4252-42.54. Kessler et al., J. Biological Chemistry, 254(16):7909-7914, Lambert, Reviews of Infectious Diseases(1991) 13 (1979). (Suppl.8):S691-5. Spiro et al., J. Biological Chemistry, 249(18):5704-5717, Dunn, et al., Reviews of Infectious Diseases(1991) 13 (Suppl.8):S657-64. (1974). Hayes et al, J. Biological Chemistry, 254(18):8777-8780, Pelczar et al, Elements of Microbiology, McGraw-Hill (1979). Book Company:New York, 1981, pp. 222-223. 5,620,964 1. 2 COMPOSITIONS FOR TREATING AND was isolated from red blood cells, and mucosal scrapings of NHIBITING GASTRIC AND DUODENAL pig stomach and human stomach. The investigators postu ULCERS lated that the material was a sulphated alkylacylglycero lipid, but the actual structure of this material was not been reported. Subsequent investigations (Lingwood et al., Infec RELATED APPLICATIONS tion and Immunity (1992) 60:2470-2474) showed that this This application is a continuation of application Ser. No. receptor is phospatidylethanolamine. 08/104.483, filed on Jul. 28, 1993, abandoned, which is a Tzovelekis et al (Infection and Immunity (1991) Continuation-in-Part of Ser. No. 07/922,519, filed on Jul. 31, 59:4252-4253) reported binding inhibition of H. pylori to 1992, abandoned. 10 HEp-2 cells by gastric mucin. The investigators observed that purified mucin showed the greatest inhibition of H. BACKGROUND OF THE INVENTION pylori binding while asialomucin exhibits somewhat dimin ished inhibition and periodate-oxidized mucin exhibited the 1. Field of the Invention lowest level of binding. On these observations, the research The present invention relates to compounds and compo ers concluded that sialic acids are at least partially respon sitions for treating and inhibiting gastric and duodenal 15 sible for the binding interaction between H. pylori and ulcers, and to methods of treating and inhibiting gastric and human gastric mucin. duodenal ulcers. Thus the binding inhibition studies all point to a H. pylori 2. Discussion of the Background binding specific receptor which possesses an N-acetyl Infection by the gram-negative, spiral, microaerophilic 20 neuraminic acid (sialic acid) (Tzouvelekis et all and Evans et bacterium Helicobacter pylori (H. pylori), formerly known al) bound in a 2->3 manner to a lactose (Evans et al). as Campylobactor pylori (C. pylori), is a primary cause of In addition to the numerous binding inhibition studies, non-autoimmune gastritis, is a factor in peptic ulcer disease methods have been pursued to treat gastric and duodenal and is more common in patients with gastric carcinoma. ulcer patients. Colloidal bismuth subcitrate (CBS) has been First isolated by Warren (Lancet (1983) 1:1273) and Marshal 25 used successfully in treating both gastric and duodenal ulcer (Lancet (1983) 1:1273-5), H. pylori has been isolated in diseases (for a review, see Lambert in Reviews of Infectious gastric tissue biopsies in patients throughout the world. Diseases (1991) 13 (Suppl. 8):S691-5. CBS has proven While the precise mechanism of inflammation is not well effective as a histamine H2 antagonist and has been asso understood, H. pylori is found in association with the apical ciated with lower relapse rates after cessation of therapy surfaces of gastric mucous-secreting cells. 30 attributed to CBS's ability to eradicate H. pylori. Bismuth Due to the site specificity of attachment, it has been subsalicylate (BSS) has also been observed to inhibit H. suggested that there are specific attachment sites for H. pylori. pylori which exist on gastric and duodenal mucous-secreting Additional studies in eliminating H. pylori have been cells. Numerous studies have been undertaken to attempt to conducted using the proton pump inhibitor, omeprazole. identify the specific binding site of H. pylori. 35 Coleman et al (U.S. Pat. No. 4,935,406) reported a Evans et al (Infection and Immunity (1988) method for relieving gastrointestinal disorder, resulting from 56:2896–2906) reported that H. pylori binding to an eryth H. pylori population, through the administration of bismuth rocyte receptor is preferentially inhibited by N-acetyl (phosph/sulfated saccharide compositions. The saccharide neuraminyl-o.(2->3)-Gal 1-4 GlcNeuAc(2->3)-lactose) compositions according to this method are simple phos as compared with NeuAc(2->6)-lactose. Sialoproteins 40 phates and sulfates of aldose and ketose monosaccharides. which contain the NeuAc(2-3)Gal isomer of NeuAc-lac Clinical trials have been reported (Evans et al, Ann. tose, i.e., human erythrocyte glycophorin A, fetuin, and Internal Med. (1991) Aug. 15, 115(4):266-9) in treating H. human o-macroglobulin, also inhibited H. pylori binding, pylori using ranitidine in conjunction with a "triple therapy' but at much higher concentrations (mg/ml) than that of amoxicillin or tetracycline, metronidazole (an antiproto observed for NeuAc(2->3)-lactose, while no inhibition was 45 zoal), and BSS. The clinical studies suggested that ulcer observed for the corresponding asialoproteins. healing was more rapid in patients receiving ranitidine plus These researchers further observed that NeuAc-lactose the "triple therapy” than in patients receiving ranitidine (also called sialyllactose) containing primarily the alone. NeuAc(2-6)Gal isomer showed no inhibition of binding, However, long-term eradication of this organism has been leading the researchers to conclude that the receptor on the 50 difficult with these therapies. The antibiotic approach runs erythrocytes is a sialoprotein containing NeuAc(2->3)Gal. the risk of the development of new antibiotic resistant Although the NeuAc(2-3)Gal moiety, which Evans et al strains.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • Research Article the Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries
    Hindawi Gastroenterology Research and Practice Volume 2019, Article ID 6532876, 7 pages https://doi.org/10.1155/2019/6532876 Research Article The Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries Jing Zhao ,1,2 Yihong Fan ,1,2 Wu Ye ,1 Wen Feng ,1 Yue Hu ,1,2 Lijun Cai ,1,2 and Bin Lu 1,2 1Department of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou 310006, China 2Key Laboratory of Digestive Pathophysiology of Zhejiang Province, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China Correspondence should be addressed to Bin Lu; [email protected] Received 16 July 2018; Accepted 28 November 2018; Published 18 June 2019 Academic Editor: Haruhiko Sugimura Copyright © 2019 Jing Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Aspirin usage is associated with increased risk of gastrointestinal bleeding. The present study explored the potential of teprenone, an antiulcerative, in preventing aspirin-related gastric mucosal injuries. Methods. 280 patients with coronary diseases, naïve to aspirin medication, were admitted between 2011 and 2013 at the First Affiliated Hospital of Zhejiang Chinese Medical University and randomized into two groups (n = 140). The aspirin group received aspirin enteric-coated tablets 100 mg/day, while the aspirin+teprenone group received teprenone 50 mg 3 times/day along with aspirin. The patients were recorded for gastrointestinal symptoms and gastric mucosal injuries during a follow-up period of 12 months with 3-month intervals.
    [Show full text]
  • Lymphoid Organs of Neonatal and Adult Mice Preferentially Produce Active Glucocorticoids from Metabolites, Not Precursors ⇑ Matthew D
    Brain, Behavior, and Immunity 57 (2016) 271–281 Contents lists available at ScienceDirect Brain, Behavior, and Immunity journal homepage: www.elsevier.com/locate/ybrbi Full-length Article Lymphoid organs of neonatal and adult mice preferentially produce active glucocorticoids from metabolites, not precursors ⇑ Matthew D. Taves a,b, , Adam W. Plumb c, Anastasia M. Korol a, Jessica Grace Van Der Gugten d, Daniel T. Holmes d, Ninan Abraham b,c,1, Kiran K. Soma a,b,e,1 a Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver V6T 1Z4, Canada b Department of Zoology, University of British Columbia, 4200-6270 University Blvd, Vancouver V6T 1Z4, Canada c Department of Microbiology and Immunology, University of British Columbia, 1365-2350 Health Sciences Mall, Vancouver V6T 1Z3, Canada d Department of Laboratory Medicine, St Paul’s Hospital, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada e Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada article info abstract Article history: Glucocorticoids (GCs) are circulating adrenal steroid hormones that coordinate physiology, especially the Received 4 March 2016 counter-regulatory response to stressors. While systemic GCs are often considered immunosuppressive, Received in revised form 22 April 2016 GCs in the thymus play a critical role in antigen-specific immunity by ensuring the selection of competent Accepted 7 May 2016 T cells. Elevated thymus-specific GC levels are thought to occur by local synthesis, but the mechanism of Available online 7 May 2016 such tissue-specific GC production remains unknown. Here, we found metyrapone-blockable GC produc- tion in neonatal and adult bone marrow, spleen, and thymus of C57BL/6 mice.
    [Show full text]
  • A Comparative Study of DA-9601 and Misoprostol for Prevention of NSAID-Associated Gastroduodenal Injury in Patients Undergoing Chronic NSAID Treatment
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Arch. Pharm. Res. (2014) 37:1308–1316 DOI 10.1007/s12272-014-0408-3 RESEARCH ARTICLE A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment Oh Young Lee • Dae-Hwan Kang • Dong Ho Lee • Il-Kwun Chung • Jae-Young Jang • Jin-Il Kim • Jin-Woong Cho • Jong-Sun Rew • Kang-Moon Lee • Kyoung Oh Kim • Myung-Gyu Choi • Sang-Woo Lee • Soo-Teik Lee • Tae-Oh Kim • Yong-Woon Shin • Sang-Yong Seol Received: 25 April 2014 / Accepted: 2 May 2014 / Published online: 30 May 2014 Ó The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Misoprostol is reported to prevent non-steroidal The primary endpoint was the gastric protection rate, and anti-inflammatory drug (NSAID)-associated gastroduode- secondary endpoints were the duodenal protection rate and nal complications. There is, however, limited information ulcer incidence rate. Endpoints were assessed by endos- regarding the efficacy of DA-9601 in this context. We copy after the 4-week treatment period. Drug-related performed a comparative study on the relative efficacy of adverse effects, including gastrointestinal (GI) symptoms, DA-9601 and misoprostol for prevention of NSAID-asso- were also compared. At week 4, the gastric protection rates ciated complications. In this multicenter, double-blinded, with DA-9601 and misoprostol were 81.4 % (192/236) and active-controlled, stratified randomized, parallel group, 89.3 % (216/242), respectively.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Aggravation by Paroxetine, a Selective Serotonin Re-Uptake Inhibitor, of Antral Lesions Generated by Nonsteroidal Anti-Inflammatory Drugs in Rats
    JPET Fast Forward. Published on June 24, 2011 as DOI: 10.1124/jpet.111.183293 JPET ThisFast article Forward. has not been Published copyedited andon formatted.June 24, The 2011 final versionas DOI:10.1124/jpet.111.183293 may differ from this version. JPET #183293 . Aggravation by Paroxetine, A Selective Serotonin Re-Uptake Inhibitor, of Antral Lesions Generated by Nonsteroidal Anti-inflammatory Drugs in Rats Downloaded from Koji Takeuchi, Akiko Tanaka, Kazuo Nukui, Azusa Kojo, Melinda Gyenge, and Kikuko Amagase jpet.aspetjournals.org at ASPET Journals on September 25, 2021 Division of Pathological Sciences Department of Pharmacology and Experimental Therapeutics Kyoto Pharmaceutical University Misasagi, Yamashina, Kyoto 607-8414, Japan (K.T., A.T., K.N., A.K., M.G., K.A.) 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on June 24, 2011 as DOI: 10.1124/jpet.111.183293 This article has not been copyedited and formatted. The final version may differ from this version. JPET #183293 . Short title: Aggravation by SSRIs of NSAID-Induced Antral Damage Address correspondence to: Dr. Koji Takeuchi Division of Pathological Sciences Department of Pharmacology and Experimental therapeutics Kyoto Pharmaceutical University Downloaded from Misasagi, Yamashina, Kyoto 607-8414, Japan Tel: (Japan) 075-595-4679; Fax: (Japan) 075-595-4774 E-mail: [email protected] jpet.aspetjournals.org Document statistics: text ------------------------ 21 pages (page 4~page 25) at ASPET Journals on September 25, 2021 figures ----------------------- 10 figures references ----------------------- 43 references (page 27~page 31) Number of words: abstract ----------------------- 247 introduction ----------------------- 410 discussion -----------------------1685 Recommended section: Gastrointestinal, Hepatic, Pulmonary, & Renal 2 JPET Fast Forward.
    [Show full text]
  • Designation of Pharmaceuticals Required Securing
    Designation of Pharmaceuticals Required securing Pharmaceutical Equivalence Ministry of Food & Drug Safety Notification No. 2014- 189 (Nov. 26, 2014, Amended) Article 1 (Purpose) In accordance with Article 31(2) and 42(1) of the 「Pharmaceutical Affairs Act」, Articles 4(1)(3) of the 「Regulation on Safety of Medicinal Products, etc.」 and Article 57 of the 「Narcotics Control Act.」, the purpose of this Notification is to set forth the appropriate standards for Pharmaceuticals approval by providing for designates pharmaceuticals required to submit bioequivalence study results and comparative clinical study results, and also designates pharmaceuticals required to submit test results of not using biological matters such as comparative dissolution test in the approval of pharmaceutical manufacturing/marketing and import. Article 2 (Designation of pharmaceuticals requiring pharmaceuticals equivalence test) ① In accordance with Article 4(1)(3)(b) of the 「Regulation on Safety of Medicinal Products, etc..」, Tablets, capsules, or suppository of which ingredients are the same as previously approved pharmaceuticals for manufacturing/marketing and import, are one of the following subparagraph. 1. Conventional pharmaceuticals, their salts and derivatives comprised of a single active pharmaceutical ingredient as listed in the attached Table 1, which are determined by the claim quantity of medical expense of health insurance submitted to the President of Health Insurance Review and Assessment Service by the healthcare institutions as described in Article 43 of the 「National Health Insurance Act」. 2. Expensive pharmaceuticals, their salts and derivatives comprise of a single active pharmaceutical ingredient as listed in the attached Table 2, which are determined by the invoiced amounts of medical expense of health insurance divided by the claim quantity submitted to the President of Health Insurance Review and Assessment Service by the healthcare institutions as described in Article 43 of the 「National Health Insurance Act」.
    [Show full text]